Skip to main content
. 2018 Jul 16;12:2223–2231. doi: 10.2147/DDDT.S163595

Figure 2.

Figure 2

Antineoplastic effects of nimotuzumab plus celecoxib on nasopharyngeal carcinoma cells. (A and B) CNE1 and CNE2 cells were treated with N50 (nimotuzumab, 50 μg/mL) or C25 (celecoxib, 25 μmol/L) or both for 24, 48 and 72 hours. Cell viability was evaluated by MTT assay. *p < 0.05, C25 + N50 vs control, C25 or N50 group at indicated time points.

Abbreviation: MTT, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide.